JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
- PMID: 27892610
- DOI: 10.1111/exd.13253
JAK inhibitor ruxolitinib inhibits the expression of cytokines characteristic of cutaneous lupus erythematosus
Abstract
This study was stimulated by the clinical observation of a rapid response of a chilblain lupus patient to treatment with JAK1/2-kinase inhibitor ruxolitinib. We investigated the in vivo expression of phospho-JAK2 in CLE skin samples as well as the immunomodulatory in vitro effect of ruxolitinib in cultured immortalized keratinocytes and in a 3D human epidermis model (epiCS). Our results demonstrate that ruxolitinib significantly decreases the production of CLE-typical cytokines (CXCL10, CXCL9, MxA) and might be a promising drug for future clinical studies in patients with CLE and related autoimmune skin diseases.
Keywords: CXCL10; JAK/STAT pathway; chilblain lupus erythematosus; interferon; kinase inhibitor.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Similar articles
-
Selective Janus Kinase 1 Inhibition Is a Promising Therapeutic Approach for Lupus Erythematosus Skin Lesions.Front Immunol. 2020 Mar 3;11:344. doi: 10.3389/fimmu.2020.00344. eCollection 2020. Front Immunol. 2020. PMID: 32194562 Free PMC article.
-
JAK1/2 Inhibitor Ruxolitinib Controls a Case of Chilblain Lupus Erythematosus.J Invest Dermatol. 2016 Jun;136(6):1281-1283. doi: 10.1016/j.jid.2016.02.015. Epub 2016 Feb 23. J Invest Dermatol. 2016. PMID: 26916391 No abstract available.
-
Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.JAMA Dermatol. 2019 Mar 1;155(3):342-346. doi: 10.1001/jamadermatol.2018.5077. JAMA Dermatol. 2019. PMID: 30673078 Free PMC article.
-
Cutaneous Lupus Erythematosus: An Update on Pathogenesis and Future Therapeutic Directions.Am J Clin Dermatol. 2023 Jul;24(4):521-540. doi: 10.1007/s40257-023-00774-8. Epub 2023 May 4. Am J Clin Dermatol. 2023. PMID: 37140884 Free PMC article. Review.
-
Management of cutaneous lupus erythematosus with Janus kinase inhibitor therapy: An evidence-based review.J Am Acad Dermatol. 2023 Jul;89(1):130-131. doi: 10.1016/j.jaad.2022.12.037. Epub 2023 Mar 18. J Am Acad Dermatol. 2023. PMID: 36935014 Review. No abstract available.
Cited by
-
Novel heterozygous TREX1 mutation in a juvenile systemic lupus erythematosus patient with severe cutaneous involvement treated successfully with Jak-inhibitors: a case report.Front Immunol. 2023 Dec 6;14:1288675. doi: 10.3389/fimmu.2023.1288675. eCollection 2023. Front Immunol. 2023. PMID: 38124732 Free PMC article.
-
Single-Cell Transcriptome Analysis Identifies Subclusters with Inflammatory Fibroblast Responses in Localized Scleroderma.Int J Mol Sci. 2023 Jun 6;24(12):9796. doi: 10.3390/ijms24129796. Int J Mol Sci. 2023. PMID: 37372943 Free PMC article.
-
Why Do We Need JAK Inhibitors in Systemic Lupus Erythematosus?Int J Mol Sci. 2022 Oct 4;23(19):11788. doi: 10.3390/ijms231911788. Int J Mol Sci. 2022. PMID: 36233087 Free PMC article. Review.
-
An update on the management of refractory cutaneous lupus erythematosus.Front Med (Lausanne). 2022 Sep 23;9:941003. doi: 10.3389/fmed.2022.941003. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213629 Free PMC article. Review.
-
The Genetic Landscape of Cutaneous Lupus Erythematosus.Front Med (Lausanne). 2022 Jun 2;9:916011. doi: 10.3389/fmed.2022.916011. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35721085 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
